Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary FibrosisDU BOIS, Roland M; WEYCKER, Derek; SZWARCBERG, Javier et al.American journal of respiratory and critical care medicine. 2011, Vol 184, Num 4, pp 459-466, issn 1073-449X, 8 p.Article

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week ResultsELION, Richard; MOLINA, Jean-Michel; CHUCK, Steven L et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 4, pp 494-497, issn 1525-4135, 4 p.Article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialDEJESUS, Edwin; ROCKSTROH, Jürgen K; CHENG, Andrew K et al.Lancet (British edition). 2012, Vol 379, Num 9835, pp 2429-2438, issn 0140-6736, 10 p.Article

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 ResultsROCKSTROH, Jürgen K; DEJESUS, Edwin; FORDYCE, Marshall W et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 5, pp 483-486, issn 1525-4135, 4 p.Article

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsNOBLE, Paul W; ALBERA, Carlo; VALEYRE, Dominique et al.Lancet (British edition). 2011, Vol 377, Num 9779, pp 1760-1769, issn 0140-6736, 10 p.Article

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1―Infected Patients: Week 48 ResultsGALLANT, Joel E; KOENIG, Ellen; YAPEI LIU et al.The Journal of infectious diseases. 2013, Vol 208, Num 1, pp 32-39, issn 0022-1899, 8 p.Article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksSAX, Paul E; DEJESUS, Edwin; WHITE, Kirsten et al.Lancet (British edition). 2012, Vol 379, Num 9835, pp 2439-2448, issn 0140-6736, 10 p.Article

Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal FunctionGERMAN, Polina; LIU, Hui C; SZWARCBERG, Javier et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 1, pp 32-40, issn 1525-4135, 9 p.Article

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialKING, Talmadge E; ALBERA, Carlo; VALEYRE, Dominique et al.Lancet (British edition). 2009, Vol 374, Num 9685, pp 222-228, issn 0140-6736, 7 p.Article